Frequently Asked Questions about Dyne Therapeutics, Inc. (DYN)

Name: Dyne Therapeutics, Inc. (DYN) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Dyne Therapeutics, Inc. (DYN) do?

Accepted Answer

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral ...

Question 2

Is Dyne Therapeutics, Inc. (DYN) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of DYN reveals an Altman Z-Score of 7.14 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if DYN fits their risk profile.

Question 3

What is the current P/E ratio for DYN?

Accepted Answer

As of the latest trading session, Dyne Therapeutics, Inc. (DYN) has a trailing P/E ratio of -5.57.

Question 4

Who is the CEO of Dyne Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Dyne Therapeutics, Inc. is John G. Cox.

Question 5

What was DYN's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Dyne Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does DYN pay a dividend?

Accepted Answer

Dyne Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does DYN have?

Accepted Answer

In its latest reporting period, Dyne Therapeutics, Inc. generated $-0.41B in Free Cash Flow against a total debt load of $0.02B.

Question 8

What is the Price-to-Book (P/B) ratio of Dyne Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Dyne Therapeutics, Inc. (DYN) is currently 2.56.

Question 9

What is the Price-to-Sales (P/S) ratio of DYN?

Accepted Answer

Based on trailing twelve-month data, Dyne Therapeutics, Inc. (DYN) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Dyne Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Dyne Therapeutics, Inc. (DYN) has a Return on Equity (ROE) of -61.45%, representing its profitability relative to shareholder equity.

DYN

Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN

Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN

Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 4.4% – Here’s Why

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript